ClinicalTrials.gg
TerminatedNCT04729387Updated Oct 19, 2026Results posted

Alpelisib Plus Olaparib in Platinum-resistant/Refractory, High-grade Serous Ovarian Cancer, With no Germline BRCA Mutation Detected

A Phase 3 interventional study of Alpelisib and Olaparib in Ovarian Cancer, sponsored by Novartis Pharmaceuticals. Terminated at 93 sites in 26 countries. Open to participants aged 18 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment

Why this study was terminated
Sponsor Decision
Updated Oct 19, 2026Study documents postedResults publication added+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
358
Allocation
Randomized
Ages
18 Years to 100 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 69 studies testing olaparib in Ovarian Neoplasms — 13 open to participants now, 26 under way, 9 of them phase 3. olaparib · Ovarian Neoplasms.

Enrollment
10th of 69
358 · median 97
Started
2021
with 3 others
Phase 3
16 of 69
2 open now
Registered
49th of 69
by date

Among the 69 studies testing olaparib in Ovarian Neoplasms, this one is the 10th largest by enrollment, is one of 4 that started in 2021, is one of 16 in phase 3, and was the 49th registered.

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

13 of the 69 studies testing olaparib in Ovarian Neoplasms are open now, in 8 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 13 open studies →

About olaparib

olaparib: first FDA approval 2014 (LYNPARZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 605 Ovarian Neoplasms studies recruiting now, 442 (73%) set no upper age limit and 107 (18%) stop at 75 or younger; 39 take children under 18; 45 take healthy volunteers.

This study: 18 Years to 100 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies testing olaparib in Ovarian Neoplasms, or all of them as a file.
02

Study summary

The objective of this study was to evaluate the efficacy and safety of alpelisib in combination with olaparib compared with single-agent cytotoxic chemotherapy in participants with platinum-resistant or platinum-refractory, germline BRCA non-mutated (gBRCAnm) high-grade serous ovarian cancer (HGSOC), with progression-free survival (PFS) as the primary efficacy endpoint.

Read the detailed description

This study enrolled adult women with platinum-resistant or platinum-refractory high-grade serous ovarian cancer (HGSOC) who did not have a detected germline BRCA mutation. In this open-label, active-controlled study, participants were randomized 1:1 to receive either alpelisib plus olaparib or single-agent cytotoxic chemotherapy (paclitaxel or pegylated liposomal doxorubicin [PLD]).

The study comprised four phases: a 28-day pre-treatment phase, a randomized treatment phase, a post-treatment follow-up phase for safety and efficacy assessments, and a post-treatment survival follow-up phase. Participants continued study treatment until disease progression, unacceptable toxicity, death, or discontinuation for any other reason.

Because the study did not achieve its primary objective, Protocol Amendment 03 removed the post-treatment survival follow-up phase. Subsequently, Protocol Amendment 04 modified the study design by removing the efficacy follow-up phase.

03

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • Alpelisib
  • olaparib
  • paclitaxel
  • pegylated liposomal doxorubicin
  • high grade
  • serous ovarian
  • fallopian or peritoneal cancer
  • no germline BRCA mutation
  • BRCA wild type
  • platinum-resistant or refractory
  • prior PARP inhibitor exposure
  • EPIK-O
04

Who can participate

The criteria were revised on the registry on Oct 19, 2026. See what changed

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion criteria:

  • Participant had confirmed diagnosis of high-grade serous or high-grade endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
  • , i.e., at least one measurable lesion per (RECIST) 1.1 criteria (a lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation).
  • If no measurable disease was present, the disease was assessable by Gynecologic Cancer Intergroup criteria (GCIC) for CA-125.
  • Participant had no germline BRCA1/2 mutation as determined by an FDA-approved assay.
  • Participant had an performance status of 0 or 1.
  • Participant had platinum-resistant (progression within one to six months after completing platinum-based therapy) or platinum disease (progression during treatment or within 4 weeks after the last dose), where platinum-based therapy was not an option, according to the Gynecologic Cancer Intergroup criteria (GCIG) 5th Ovarian Cancer Consensus Conference definitions.
  • Participant must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy was appropriate as the next .
  • Participant had received prior bevacizumab or was not eligible to receive bevacizumab due to medical reasons.

Key Exclusion criteria:

  • Participant had received prior treatment with any phosphoinositide 3-kinase, mammalian Target Of Rapamycin or Protein Kinase B inhibitor.
  • Participant was concurrently using other anti-cancer therapy.
  • Participant was in a state of small or large bowel obstruction or had other impairment of gastrointestinal (GI) function or GI disease.
  • Participant had surgery within 14 days prior to starting study drug or had not recovered from major adverse effects.
  • Participant had not recovered from all toxicities related to prior anticancer therapies to baseline or National Cancer Institute (NCI) (CTCAE) Version 4.03 Grade ≤1. Exception to this criterion: participants with any grade of alopecia were allowed to enter the study.
  • Participant had an established diagnosis of diabetes mellitus type I or uncontrolled type II based on fasting plasma glucose and .
  • Participants with liver impairment and score B or C.
  • Participant had received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to randomization, and who had not recovered to baseline, grade 1 or better from related adverse effects of such therapy (with the exception of alopecia).
  • Participant had known to any of the study drugs or .
  • Participant had a history of myelodysplastic syndrome or acute myeloid leukemia, or presented clinical and/ or laboratory features suggestive thereof.

Other inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
358 participants (actual)

Study arms

  • Experimental
    Alpelisib+olaparib

    Alpelisib (200 mg once daily after food) and Olaparib (200 mg twice daily) were both administered orally on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.

    Drug: Alpelisib · Drug: Olaparib

  • Active comparator
    Paclitaxel or Pegylated liposomal doxorubicin

    Paclitaxel (80 mg/m²) was administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle, or Pegylated liposomal doxorubicin (40-50 mg/m² at physician discretion) was administered as an intravenous infusion once every 28 days starting on Cycle 1 Day 1.

    Drug: Paclitaxel · Drug: Pegylated liposomal doxorubicin (PLD)

Interventions

  • Alpelisib was administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle

    Also known as: BYL719

  • Olaparib was administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.

  • Paclitaxel (80 mg/m²) was administered as a weekly intravenous infusion on Days 1, 8, 15, and 22 of each 28-day cycle.

  • Pegylated liposomal doxorubicin (40-50 mg/m² at physician discretion) was administered as an intravenous infusion once every 28 days starting on Cycle 1 Day 1.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Based on Blinded Independent Review Committee (BIRC) Assessment Using RECIST 1.1 Criteria

    Progression-free survival (PFS) was defined as the time from randomization to the first documented disease progression or death from any cause, as determined by blinded independent review committee (BIRC) assessment. Participants without an event were censored at the date of their last adequate tumor assessment. Clinical deterioration without objective radiologic evidence was not considered disease progression in the primary efficacy analysis. Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including baseline), with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of non-target lesions.

    Time frame: From randomization until the date of the first documented progression or death due to any cause, whichever comes first, assessed up to approximately 21 months

Secondary outcomes

  1. Overall Survival

    Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If a participant was not known to have died, OS was censored at the latest date the participant was known to be alive (on or before the cut-off date), i.e., the last known date the participant was alive (last contact date).

    Time frame: From randomization until death, assessed up to approximately 44 months

  2. Overall Response Rate (ORR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1 Criteria

    Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) by blinded independent review committee (BIRC) assessment as per RECIST 1.1 criteria: * CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. * PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

    Time frame: Up to approximately 21 months

  3. Clinical Benefit Rate (CBR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1

    Clinical benefit rate (CBR) with confirmed response was defined as the percentage of participants whose best overall response was a confirmed CR or PR, or stable disease (SD) maintained for at least 24 weeks. CR, PR, and SD were determined by BIRC according to RECIST 1.1 criteria.

    Time frame: Up to approximately 21 months

  4. Time to Response (TTR) Based on BIRC Assessment and According to RECIST 1.1

    Time to response (TTR) was defined as the interval from randomization to the first documented occurrence of either complete response (CR) or partial response (PR), which was subsequently confirmed (using the date of initial response, not the confirmation date). CR and PR were determined based on tumor response data assessed by BIRC according to RECIST 1.1 criteria.

    Time frame: From the date of randomization to the first documented response, assessed through Month 12

  5. Duration of Response (DOR) With Confirmed Response Based on BIRC Assessment and According to RECIST 1.1

    Duration of response (DOR) with confirmed response was calculated only for participants whose best overall response was a confirmed complete response (CR) or confirmed partial response (PR), based on tumor response data assessed by BIRC according to RECIST 1.1. The start date was the date of the first documented CR or PR (i.e., the initial response date, not the confirmation date), and the end date was the date of first documented disease progression or death due to underlying cancer. Participants without progression or cancer-related death were censored at the date of their last adequate tumor assessment.

    Time frame: From first documented response to first documented progression or death, assessed up to approximately 21 months

  6. Time to Definitive Deterioration of the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

    Performance status (PS) was evaluated using the ECOG scale, which comprises six grades (0 to 5), where 0 represents fully active and 5 represents death. Time to definitive deterioration in ECOG PS was defined as the interval from randomization to the date when ECOG PS worsened by at least one category from baseline and remained worsened. Deterioration was considered definitive if there was no subsequent improvement to the baseline category or better. Participants were censored if no definitive deterioration occurred before the earlier of: (i) the analysis cut-off date or (ii) initiation of a new anti-neoplastic therapy. The censoring date was the date of the last PS assessment prior to the cut-off or start of new therapy.

    Time frame: Up to approximately 18 months

  7. Number of Participants With Dose Interruptions and Dose Reductions

    The number of participants with dose reductions/interruptions was assessed and summarized by study treatment.

    Time frame: From randomization until end of treatment, assessed up to approximately 39 months with alpelisib or olaparib, 45 months with paclitaxel, and 23 months with pegylated liposomal doxorubicin (PLD)

  8. Dose Intensity for Alpelisib and Olaparib

    Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.

    Time frame: From randomization until end of treatment, assessed up to approximately 39 months

  9. Dose Intensity for Paclitaxel

    Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.

    Time frame: From randomization until end of treatment, assessed up to approximately 45 months

  10. Dose Intensity for Pegylated Liposomal Doxorubicin

    Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.

    Time frame: From randomization until end of treatment, assessed up to approximately 23 months

  11. Area Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and Olaparib

    Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUCtau was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)

  12. Area Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of Alpelisib and Olaparib

    Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUClast was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)

  13. Maximum Concentration (Cmax) of Alpelisib and Olaparib

    Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. Cmax was listed and summarized using descriptive statistics.

    Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)

  14. Time to Reach Maximum Concentration (Tmax) of Alpelisib and Olaparib

    Venous blood samples were collected to characterize the pharmacokinetics (PK) of alpelisib when administered in combination with olaparib. Time to maximum observed plasma concentration (Tmax) was calculated using actual sample collection times rather than nominal scheduled sampling times and was summarized using descriptive statistics.

    Time frame: Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)

  15. Time to Definitive Deterioration by 10% in FACT-O Trial Outcomes Index (TOI) Score

    The Functional Assessment of Cancer Therapy-Ovarian (FACT O) is a validated instrument that evaluates quality of life in patients with ovarian cancer. The Trial Outcome Index (TOI) of the FACT-O combines Physical Well Being (PWB), Functional Well Being (FWB), and the Ovarian Cancer Subscale (OCS), and its scores range from 0 to 100, with higher scores indicating better quality of life and physical/functional status. Time to definitive deterioration by 10% in FACT O TOI is defined as the time from randomization to the first occurrence of at least a 10% worsening from baseline with no subsequent improvement above this threshold, or death. Participants without an event before analysis cut off or before starting another anticancer therapy were censored at their last adequate assessment. Time to deterioration was estimated using the Kaplan-Meier method.

    Time frame: Baseline, up to 15 months

07

Results

Posted Jun 4, 2026

Participant flow

The study was conducted globally across 94 centers in 26 countries.

Participant flow — Overall Study
MilestoneAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Started180178
Safety set (saf)180164
Completed00
Not completed180178
Withdrew: Randomized, not treated014
Withdrew: Progressive disease (pd) per local blinded independent review committee (birc)7570
Withdrew: Physician decision2230
Withdrew: Progressive disease (pd) per local investigator2030
Withdrew: Adverse event2710
Withdrew: Subject decision2411
Withdrew: Death119
Withdrew: No pd per birc or local investigator recorded before end of treatment (eot) with reason pd13
Withdrew: Study terminated by sponsor01

Outcome measures

PrimaryProgression Free Survival (PFS) Based on Blinded Independent Review Committee (BIRC) Assessment Using RECIST 1.1 Criteria

Progression-free survival (PFS) was defined as the time from randomization to the first documented disease progression or death from any cause, as determined by blinded independent review committee (BIRC) assessment. Participants without an event were censored at the date of their last adequate tumor assessment. Clinical deterioration without objective radiologic evidence was not considered disease progression in the primary efficacy analysis. Disease progression was defined according to Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1, as a ≥20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (including baseline), with an absolute increase of at least 5 mm, the appearance of one or more new lesions, or unequivocal progression of non-target lesions.

Time frame:
From randomization until the date of the first documented progression or death due to any cause, whichever comes first, assessed up to approximately 21 months
Reported as:
Median · Months
Progression Free Survival (PFS) Based on Blinded Independent Review Committee (BIRC) Assessment Using RECIST 1.1 Criteria
MonthsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Progression Free Survival (PFS) Based on Blinded Independent Review Committee (BIRC) Assessment Using RECIST 1.1 Criteria3.6 (3.35 to 4.27)3.9 (3.68 to 5.36)
Statistical analysis
  • Alpelisib 200mg + Olaparib 200mg vs Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) · Log Rank · p = 0.84 · Hazard ratio (hr): 1.142 · 95% CI 0.882 to 1.478Both Log-rank test and Cox PH model are stratified using IRT data by (i) Time to relapse from last platinum dose (\< 3 months vs. \>= 3 and \<= 6 months), (ii) Prior PARP inhibitor use (yes vs. no), (iii) Prior bevacizumab use (yes vs. no).
SecondaryOverall Survival

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If a participant was not known to have died, OS was censored at the latest date the participant was known to be alive (on or before the cut-off date), i.e., the last known date the participant was alive (last contact date).

Time frame:
From randomization until death, assessed up to approximately 44 months
Reported as:
Median · Months
Overall Survival
MonthsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Overall Survival12.45 (8.44 to 15.01)11.99 (10.18 to 14.19)
SecondaryOverall Response Rate (ORR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1 Criteria

Overall Response Rate (ORR) was defined as the proportion of participants with best overall response (BOR) of complete response (CR) or partial response (PR) by blinded independent review committee (BIRC) assessment as per RECIST 1.1 criteria: * CR = Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \< 10 mm. * PR = At least a 30% decrease in the sum of diameter of all target lesions, taking as reference the baseline sum of diameters.

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1 Criteria
Percentage of participantsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Overall Response Rate (ORR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1 Criteria15.6 (10.6 to 21.7)13.5 (8.8 to 19.4)
SecondaryClinical Benefit Rate (CBR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1

Clinical benefit rate (CBR) with confirmed response was defined as the percentage of participants whose best overall response was a confirmed CR or PR, or stable disease (SD) maintained for at least 24 weeks. CR, PR, and SD were determined by BIRC according to RECIST 1.1 criteria.

Time frame:
Up to approximately 21 months
Reported as:
Number · Percentage of participants
Clinical Benefit Rate (CBR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.1
Percentage of participantsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Clinical Benefit Rate (CBR) With Confirmed Response Based on BIRC Assessment According to RECIST 1.121.1 (15.4 to 27.8)19.1 (13.6 to 25.7)
SecondaryTime to Response (TTR) Based on BIRC Assessment and According to RECIST 1.1

Time to response (TTR) was defined as the interval from randomization to the first documented occurrence of either complete response (CR) or partial response (PR), which was subsequently confirmed (using the date of initial response, not the confirmation date). CR and PR were determined based on tumor response data assessed by BIRC according to RECIST 1.1 criteria.

Time frame:
From the date of randomization to the first documented response, assessed through Month 12
Reported as:
Median · Months
Time to Response (TTR) Based on BIRC Assessment and According to RECIST 1.1
MonthsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Time to Response (TTR) Based on BIRC Assessment and According to RECIST 1.1NA (NA to NA)NA (NA to NA)
SecondaryDuration of Response (DOR) With Confirmed Response Based on BIRC Assessment and According to RECIST 1.1

Duration of response (DOR) with confirmed response was calculated only for participants whose best overall response was a confirmed complete response (CR) or confirmed partial response (PR), based on tumor response data assessed by BIRC according to RECIST 1.1. The start date was the date of the first documented CR or PR (i.e., the initial response date, not the confirmation date), and the end date was the date of first documented disease progression or death due to underlying cancer. Participants without progression or cancer-related death were censored at the date of their last adequate tumor assessment.

Time frame:
From first documented response to first documented progression or death, assessed up to approximately 21 months
Reported as:
Median · Months
Duration of Response (DOR) With Confirmed Response Based on BIRC Assessment and According to RECIST 1.1
MonthsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Duration of Response (DOR) With Confirmed Response Based on BIRC Assessment and According to RECIST 1.17.36 (4.96 to 12.94)5.5 (3.78 to NA)
SecondaryTime to Definitive Deterioration of the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)

Performance status (PS) was evaluated using the ECOG scale, which comprises six grades (0 to 5), where 0 represents fully active and 5 represents death. Time to definitive deterioration in ECOG PS was defined as the interval from randomization to the date when ECOG PS worsened by at least one category from baseline and remained worsened. Deterioration was considered definitive if there was no subsequent improvement to the baseline category or better. Participants were censored if no definitive deterioration occurred before the earlier of: (i) the analysis cut-off date or (ii) initiation of a new anti-neoplastic therapy. The censoring date was the date of the last PS assessment prior to the cut-off or start of new therapy.

Time frame:
Up to approximately 18 months
Reported as:
Median · Months
Time to Definitive Deterioration of the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)
MonthsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Time to Definitive Deterioration of the Eastern Cooperative Oncology Group (ECOG) Performance Status (PS)6.0 (3.98 to 8.31)7.4 (4.24 to NA)
SecondaryNumber of Participants With Dose Interruptions and Dose Reductions

The number of participants with dose reductions/interruptions was assessed and summarized by study treatment.

Time frame:
From randomization until end of treatment, assessed up to approximately 39 months with alpelisib or olaparib, 45 months with paclitaxel, and 23 months with pegylated liposomal doxorubicin (PLD)
Reported as:
Count of participants · Participants
Number of Participants With Dose Interruptions and Dose Reductions
ParticipantsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Alpelisib — Participants with no dose reduction and/or interruption53—
Alpelisib — Participants with at least one dose reduction and/or interruption127—
Olaparib — Participants with no dose reduction and/or interruption63—
Olaparib — Participants with at least one dose reduction and/or interruption117—
Paclitaxel — Participants with no dose reduction and/or interruption—33
Paclitaxel — Participants with at least one dose reduction and/or interruption—37
Pegylated liposomal Doxorubicin (PLD) — Participants with no dose reduction and/or interruption—81
Pegylated liposomal Doxorubicin (PLD) — Participants with at least one dose reduction and/or interruption—13
SecondaryDose Intensity for Alpelisib and Olaparib

Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.

Time frame:
From randomization until end of treatment, assessed up to approximately 39 months
Reported as:
Median · mg/day
Dose Intensity for Alpelisib and Olaparib
mg/dayAlpelisib 200mg + Olaparib 200mg
Alpelisib181.2 (62.8 to 201.8)
Olaparib383.7 (103.4 to 400)
SecondaryDose Intensity for Paclitaxel

Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.

Time frame:
From randomization until end of treatment, assessed up to approximately 45 months
Reported as:
Median · mg/m^2/7 days
Dose Intensity for Paclitaxel
mg/m^2/7 daysPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Dose Intensity for Paclitaxel71.1 (35.4 to 84)
SecondaryDose Intensity for Pegylated Liposomal Doxorubicin

Dose intensity was computed as the ratio of actual cumulative dose received to actual duration of exposure and summarized by study treatment.

Time frame:
From randomization until end of treatment, assessed up to approximately 23 months
Reported as:
Median · mg/m^2/28-days
Dose Intensity for Pegylated Liposomal Doxorubicin
mg/m^2/28-daysPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Dose Intensity for Pegylated Liposomal Doxorubicin40 (10 to 50.5)
SecondaryArea Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and Olaparib

Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUCtau was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and Olaparib
hr*ng/mLAlpelisib 200mg + Olaparib 200mg
Alpelisib22194.3 ± 51.1
Olaparib39939.1 ± 59.1
SecondaryArea Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of Alpelisib and Olaparib

Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. AUClast was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of Alpelisib and Olaparib
hr*ng/mLAlpelisib 200mg + Olaparib 200mg
Alpelisib19806.8 ± 63.8
Olaparib2783.4 ± 82.2
SecondaryMaximum Concentration (Cmax) of Alpelisib and Olaparib

Venous whole blood samples were collected to characterize the pharmacokinetics of alpelisib when administered in combination with olaparib. Cmax was listed and summarized using descriptive statistics.

Time frame:
Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Reported as:
Mean · ng/mL
Maximum Concentration (Cmax) of Alpelisib and Olaparib
ng/mLAlpelisib 200mg + Olaparib 200mg
Alpelisib2029.3 ± 871.29
Olaparib7313.2 ± 2429.27
SecondaryTime to Reach Maximum Concentration (Tmax) of Alpelisib and Olaparib

Venous blood samples were collected to characterize the pharmacokinetics (PK) of alpelisib when administered in combination with olaparib. Time to maximum observed plasma concentration (Tmax) was calculated using actual sample collection times rather than nominal scheduled sampling times and was summarized using descriptive statistics.

Time frame:
Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
Reported as:
Median · hour (hr)
Time to Reach Maximum Concentration (Tmax) of Alpelisib and Olaparib
hour (hr)Alpelisib 200mg + Olaparib 200mg
Alpelisib2.4 (0 to 8.2)
Olaparib2.0 (0 to 6.0)
SecondaryTime to Definitive Deterioration by 10% in FACT-O Trial Outcomes Index (TOI) Score

The Functional Assessment of Cancer Therapy-Ovarian (FACT O) is a validated instrument that evaluates quality of life in patients with ovarian cancer. The Trial Outcome Index (TOI) of the FACT-O combines Physical Well Being (PWB), Functional Well Being (FWB), and the Ovarian Cancer Subscale (OCS), and its scores range from 0 to 100, with higher scores indicating better quality of life and physical/functional status. Time to definitive deterioration by 10% in FACT O TOI is defined as the time from randomization to the first occurrence of at least a 10% worsening from baseline with no subsequent improvement above this threshold, or death. Participants without an event before analysis cut off or before starting another anticancer therapy were censored at their last adequate assessment. Time to deterioration was estimated using the Kaplan-Meier method.

Time frame:
Baseline, up to 15 months
Reported as:
Median · Months
Time to Definitive Deterioration by 10% in FACT-O Trial Outcomes Index (TOI) Score
MonthsAlpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)
Time to Definitive Deterioration by 10% in FACT-O Trial Outcomes Index (TOI) Score3.7 (2.4 to 4.2)3.8 (2.1 to 11.1)

Adverse events

Collected over Adverse events (AEs) were collected from the first dose of study treatment through 30 days after the last dose (on-treatment period), for up to approximately 39 months with alpelisib or olaparib, 45 months with paclitaxel, and 23 months with pegylated liposomal doxorubicin (PLD). Deaths occurring the post-treatment period were collected through study completion, including an additional follow-up period of approximately 14, 8, and 30 months, respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Alpelisib 200mg + Olaparib 200mg (On-Treatment)27/180 (15%)98/180 (54.4%)176/180 (97.8%)
Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (On-Treatment)7/178 (3.9%)52/164 (31.7%)156/164 (95.1%)
Alpelisib 200mg + Olaparib 200mg (Post-Treatment)90/180 (50%)——
Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (Post-Treatment)93/178 (52.2%)——
Most frequent serious events
Showing 10 of 119
Most frequent serious events
EventAlpelisib 200mg + Olaparib 200mg (On-Treatment)Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (On-Treatment)Alpelisib 200mg + Olaparib 200mg (Post-Treatment)Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (Post-Treatment)
Malignant gastrointestinal obstructionGastrointestinal disorders8/18013/164——
NauseaGastrointestinal disorders12/1801/164——
AscitesGastrointestinal disorders6/18010/164——
VomitingGastrointestinal disorders10/1801/164——
HyperglycaemiaMetabolism and nutrition disorders9/1800/164——
Pleural effusionRespiratory, thoracic and mediastinal disorders7/1802/164——
PneumoniaInfections and infestations6/1804/164——
DyspnoeaRespiratory, thoracic and mediastinal disorders6/1802/164——
Intestinal obstructionGastrointestinal disorders1/1805/164——
Acute kidney injuryRenal and urinary disorders5/1800/164——
Most frequent other events
Showing 10 of 52
Most frequent other events
EventAlpelisib 200mg + Olaparib 200mg (On-Treatment)Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (On-Treatment)Alpelisib 200mg + Olaparib 200mg (Post-Treatment)Paclitaxel or Pegylated Liposomal Doxorubicin (PLD) (Post-Treatment)
NauseaGastrointestinal disorders111/18051/164——
HyperglycaemiaMetabolism and nutrition disorders91/1806/164——
DiarrhoeaGastrointestinal disorders77/18029/164——
VomitingGastrointestinal disorders74/18033/164——
AnaemiaBlood and lymphatic system disorders68/18060/164——
Decreased appetiteMetabolism and nutrition disorders62/18027/164——
FatigueGeneral disorders52/18031/164——
Abdominal painGastrointestinal disorders44/18032/164——
ConstipationGastrointestinal disorders40/18030/164——
AstheniaGeneral disorders35/18036/164——

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Alpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)Total
Mean60 ± 9.9161 ± 9.5260.5 ± 9.72
Sex: Female, Male
Sex: Female, Male(Participants)Alpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)Total
Female180178358
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Alpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)Total
American Indian or Alaska Native000
Asian483179
Native Hawaiian or Other Pacific Islander000
Black or African American426
White121139260
More than one race011
Unknown or Not Reported7512
Eastern Cooperative Oncology Group (ECOG) performance status (PS)
Eastern Cooperative Oncology Group (ECOG) performance status (PS)(Participants)Alpelisib 200mg + Olaparib 200mgPaclitaxel or Pegylated Liposomal Doxorubicin (PLD)Total
Grade 0: Fully active, able to carry on all pre-disease performance without restriction.115109224
Grade 1: Limited strenuous activity; ambulatory and able to do light or sedentary work.6468132
Grade 2: Self-care capable, ambulatory; no work; active >50% of waking hours.101
Grade 3: Capable of only limited self-care; confined to bed or chair more than 50% of waking hours.000
Grade 4: Completely disabled; cannot carry on any self-care; totally confined to bed or chair.000
Grade 5: Dead000
Missing011
08

Study locations

93 sites
  • Arizona Oncology Associates
    Phoenix, Arizona 85016, United States
  • HonorHealth
    Phoenix, Arizona 85016, United States
  • Florida Cancer Specialists
    Fort Myers, Florida 33901, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Maryland Oncology Hematology P A
    Silver Spring, Maryland 20904, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02115, United States
  • Memorial Sloan Kettering Cancer Ctr
    New York, New York 10065, United States
  • Oncology Hematology Care Inc
    Cincinnati, Ohio 45242, United States
  • University Of Cincinnati
    Cincinnati, Ohio 45267, United States
  • Avera Cancer Institute
    Sioux Falls, South Dakota 57106, United States
  • Tennessee Oncology
    Nashville, Tennessee 37203, United States
  • Texas Oncology
    Amarillo, Texas 79124, United States
  • Texas Oncology P A
    Bedford, Texas 76022, United States
  • Texas Oncology P A
    San Antonio, Texas 78217, United States
  • Texas Oncology Northeast Texas
    Tyler, Texas 75702, United States
  • Novartis Investigative Site
    CABA, Buenos Aires C1125ABD, Argentina
  • Novartis Investigative Site
    Buenos Aires, C1012AAR, Argentina
  • Novartis Investigative Site
    Caba, C1015ABO, Argentina
  • Novartis Investigative Site
    Bedford Park, South Australia 5041, Australia
  • Novartis Investigative Site
    Shepparton, Victoria 3630, Australia
  • Novartis Investigative Site
    Sydney, 2031, Australia
  • Novartis Investigative Site
    Innsbruck, Tyrol 6020, Austria
  • Novartis Investigative Site
    Graz, 8036, Austria
  • Novartis Investigative Site
    Brussels, 1000, Belgium
  • Novartis Investigative Site
    Leuven, 3000, Belgium
  • Novartis Investigative Site
    Namur, 5000, Belgium
  • Novartis Investigative Site
    Belo Horizonte, Minas Gerais 30130-100, Brazil
  • Novartis Investigative Site
    São Paulo, São Paulo 04014-002, Brazil
  • Novartis Investigative Site
    Calgary, Alberta T2N 5G2, Canada
  • Novartis Investigative Site
    Vancouver, British Columbia V5Z 4E6, Canada
  • Novartis Investigative Site
    London, Ontario N6A 5W9, Canada
  • Novartis Investigative Site
    Toronto, Ontario M4N 3M5, Canada
  • Novartis Investigative Site
    Chengdu, Sichuan 610041, China
  • Novartis Investigative Site
    Beijing, 100036, China
  • Novartis Investigative Site
    Jinan, 250012, China
  • Novartis Investigative Site
    Shanghai, 200032, China
  • Novartis Investigative Site
    Tianjin, 300480, China
  • Novartis Investigative Site
    Ostrava, Poruba 708 52, Czechia
  • Novartis Investigative Site
    Nový Jičín, 741 01, Czechia
  • Novartis Investigative Site
    Prague, 128 08, Czechia
  • Novartis Investigative Site
    Herlev, 2730, Denmark
  • Novartis Investigative Site
    Odense C, 5000, Denmark
  • Novartis Investigative Site
    Kuopio, 70211, Finland
  • Novartis Investigative Site
    Tampere, 33521, Finland
  • Novartis Investigative Site
    Turku, 20521, Finland
  • Novartis Investigative Site
    Besançon, 25030, France
  • Novartis Investigative Site
    Lyon, 69373, France
  • Novartis Investigative Site
    Paris, 75012, France
  • Novartis Investigative Site
    Pierre-Bénite, 69495, France
  • Novartis Investigative Site
    Villejuif, 94800, France
  • Novartis Investigative Site
    Mannheim, Baden-Wurttemberg 68305, Germany
  • Novartis Investigative Site
    Dresden, Saxony 01307, Germany
  • Novartis Investigative Site
    Berlin, 13353, Germany
  • Novartis Investigative Site
    Essen, 45136, Germany
  • Novartis Investigative Site
    Bologna, BO 40138, Italy
  • Novartis Investigative Site
    Florence, FI 50134, Italy
  • Novartis Investigative Site
    Milan, MI 20133, Italy
  • Novartis Investigative Site
    Milan, MI 20141, Italy
  • Novartis Investigative Site
    Roma, RM 00168, Italy
  • Novartis Investigative Site
    Vicenza, VI 36100, Italy
  • Novartis Investigative Site
    Naples, 80131, Italy
  • Novartis Investigative Site
    Kuala Lumpur, Kuala Lumpur 50586, Malaysia
  • Novartis Investigative Site
    Kota Kinabalu, Sabah 88996, Malaysia
  • Novartis Investigative Site
    Kuching, Sarawak 93586, Malaysia
  • Novartis Investigative Site
    Kuala Lumpur, 59100, Malaysia
  • Novartis Investigative Site
    Monterrey, Nuevo León 64460, Mexico
  • Novartis Investigative Site
    Mexico City, 04700, Mexico
  • Novartis Investigative Site
    Eindhoven, 5623 EJ, Netherlands
  • Novartis Investigative Site
    Loures, 2674-514, Portugal
  • Novartis Investigative Site
    Porto, 4200-072, Portugal
  • Novartis Investigative Site
    Arkhangelsk, 163045, Russia
  • Novartis Investigative Site
    Singapore, 119074, Singapore
  • Novartis Investigative Site
    Singapore, 168583, Singapore
  • Novartis Investigative Site
    Bratislava, 83310, Slovakia
  • Novartis Investigative Site
    Seoul, 03080, South Korea
  • Novartis Investigative Site
    Seoul, 03722, South Korea
  • Novartis Investigative Site
    Pamplona, Navarre 31008, Spain
  • Novartis Investigative Site
    Barcelona, 08035, Spain
  • Novartis Investigative Site
    Barcelona, 08036, Spain
  • Novartis Investigative Site
    Córdoba, 14004, Spain
  • Novartis Investigative Site
    Madrid, 28034, Spain
  • Novartis Investigative Site
    Valencia, 46010, Spain
  • Novartis Investigative Site
    Taichung, 407219, Taiwan
  • Novartis Investigative Site
    Taipei, 10002, Taiwan
  • Novartis Investigative Site
    Taipei, 11217, Taiwan
  • Novartis Investigative Site
    Izmir, Karsiyaka 35575, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, Sihhiye-Altindag 06230, Turkey (Türkiye)
  • Novartis Investigative Site
    Adana, Yuregir 01230, Turkey (Türkiye)
  • Novartis Investigative Site
    Ankara, 06520, Turkey (Türkiye)
  • Novartis Investigative Site
    Glasgow, G12 0YN, United Kingdom
  • Novartis Investigative Site
    London, SE1 9RT, United Kingdom
  • Novartis Investigative Site
    Manchester, M20 2BX, United Kingdom
09

References and documents

Publications

  • Konstantinopoulos PA, Gonzalez-Martin A, Cruz FM, Friedlander M, Glasspool R, Lorusso D, Marth C, Monk BJ, Kim JW, Hinson P, Ajipa O, Pretre V, Han Y, Matulonis UA. EPIK-O/ENGOT-OV61: alpelisib plus olaparib vs cytotoxic chemotherapy in high-grade serous ovarian cancer (phase III study). Future Oncol. 2022 Oct;18(31):3481-3492. doi: 10.2217/fon-2022-0666. Epub 2022 Sep 6. PubMed 36066851 ↗
  • Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortes-Salgado A, Zamagni C, Marme F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, Gonzalez-Martin A. Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation. J Clin Oncol. 2025 Sep 10;43(26):2908-2917. doi: 10.1200/JCO-25-00225. Epub 2025 Jul 23. PubMed 40700681 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2021 to primary completion in Apr 2023, 20 months.

Results were first posted in Jun 2026, 3 years 1 month after primary completion. A results delay was requested in Apr 2024.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2021
First posted
Jan 28, 2021
StartActual
Jul 22, 2021
Primary completionActual
Apr 21, 2023
CompletionActual
Jan 19, 2026
Results delay requested
Apr 17, 2024
Results first posted
Jun 4, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Posted results revised
revised Oct 19, 2026
Sites
1 site added, 1 site removed
Show site
  • Novartis Investigative Site · Milan, Italy
Show 1 removed
  • Novartis Investigative Site · Milan, Italy
Oct 19, 2026
Eligibility
17 criteria edited
What changed in the criteria
  • EditedParticipant hashad histologically confirmed diagnosis of high-grade serous or high-grade endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
  • EditedMeasurable disease, i.e., at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (a lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation).
  • EditedIf no measurable disease iswas present, the disease should bewas assessable by Gynecologic Cancer Intergroup criteria (GCIC) for CA-125.
  • EditedParticipant hashad no germline BRCA1/2 mutation as determined by an FDA-approved assay.
  • EditedParticipant hashad an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • EditedParticipant hashad platinum-resistant (progression within one to six months after completing platinum-based therapy) or platinum refractory disease (progression during treatment or within 4 weeks after the last dose), where platinum-based therapy iswas not an option, according to the Gynecologic Cancer Intergroup criteria (GCIG) 5th Ovarian Cancer Consensus Conference definitions (Wilson et al 2016). The platinum-based chemotherapy regimen does not necessarily need to be the last regimen the participant received prior to study entry
  • EditedParticipant must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy iswas appropriate as the next line of treatment.
  • EditedParticipant hashad received prior bevacizumab or iswas not eligible to receive bevacizumab due to medical reasons.
  • EditedParticipant hashad received prior treatment with any PI3Kphosphoinositide 3-kinase, mTORmammalian Target Of Rapamycin or AKTProtein Kinase B inhibitor.
  • EditedParticipant iswas concurrently using other anti-cancer therapy.
  • EditedParticipant iswas in a state of small or large bowel obstruction or hashad other impairment of gastrointestinal (GI) function or GI disease.
  • EditedParticipant has had surgery within 14 days prior to starting study drug or hashad not recovered from major adverse effects.
  • EditedParticipant hashad not recovered from all toxicities related to prior anticancer therapies to baseline or National Cancer Institute (NCI ) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 Grade ≤1. Exception to this criterion: participants with any grade of alopecia arewere allowed to enter the study.
  • EditedParticipant hashad an established diagnosis of diabetes mellitus type I or uncontrolled type II based on fasting plasma glucose and HbA1c.
  • EditedParticipant hashad received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to randomization, and who hashad not recovered to baseline, grade 1 or better from related adverse effects of such therapy (with the exception of alopecia).
  • EditedParticipant has ahad known hypersensitivity to any of the study drugs or excipients.
  • EditedParticipant hashad a history of myelodysplastic syndrome or acute myeloid leukemia, or presentspresented clinical and/ or laboratory features suggestive thereof.
Oct 19, 2026
Documents
Oct 19, 2026
Publications
Results publication added: Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D,… PubMed 40700681 ↗
Oct 19, 2026
Secondary outcomes
1 edited, 7 time frame changed, 4 description edited
What changed in the outcomes
  • EditedArea Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of Alpelisib and OlaparibTime frame: Day 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
  • Time frameNumber of Participants With Dose Interruptions and Dose ReductionsFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 39 months with alpelisib or olaparib, 45 months with paclitaxel, and 23 months with pegylated liposomal doxorubicin (PLD)
  • Time frameDose Intensity for Alpelisib and OlaparibFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 39 months
  • Time frameDose Intensity for PaclitaxelFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 45 months
  • Time frameDose Intensity for Pegylated Liposomal DoxorubicinFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 23 months
  • Time frameArea Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and OlaparibDay 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
  • Time frameMaximum Concentration (Cmax) of Alpelisib and OlaparibDay 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
  • Time frameTime to Reach Maximum Concentration (Tmax) of Alpelisib and OlaparibDay 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
  • DescriptionArea Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and Olaparib: how it is measured was reworded
  • DescriptionMaximum Concentration (Cmax) of Alpelisib and Olaparib: how it is measured was reworded
  • DescriptionOverall Survival: how it is measured was reworded
  • DescriptionTime to Reach Maximum Concentration (Tmax) of Alpelisib and Olaparib: how it is measured was reworded
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Posted results revised
    Documents Study protocol ↗ updated
    Publications Results publication added: Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D,… PubMed 40700681 ↗
    1 site added, 1 site removed
    Show site
    • Novartis Investigative Site · Milan, Italy
    Show 1 removed
    • Novartis Investigative Site · Milan, Italy
    Eligibility 17 criteria edited
    What changed in the criteria
    • EditedParticipant hashad histologically confirmed diagnosis of high-grade serous or high-grade endometrioid ovarian cancer, fallopian tube cancer, or primary peritoneal cancer.
    • EditedMeasurable disease, i.e., at least one measurable lesion per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria (a lesion at a previously irradiated site may only be counted as a target lesion if there is clear sign of progression since the irradiation).
    • EditedIf no measurable disease iswas present, the disease should bewas assessable by Gynecologic Cancer Intergroup criteria (GCIC) for CA-125.
    • EditedParticipant hashad no germline BRCA1/2 mutation as determined by an FDA-approved assay.
    • EditedParticipant hashad an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
    • EditedParticipant hashad platinum-resistant (progression within one to six months after completing platinum-based therapy) or platinum refractory disease (progression during treatment or within 4 weeks after the last dose), where platinum-based therapy iswas not an option, according to the Gynecologic Cancer Intergroup criteria (GCIG) 5th Ovarian Cancer Consensus Conference definitions (Wilson et al 2016). The platinum-based chemotherapy regimen does not necessarily need to be the last regimen the participant received prior to study entry
    • EditedParticipant must have received at least one but no more than three prior systemic treatment regimens and for whom single-agent chemotherapy iswas appropriate as the next line of treatment.
    • EditedParticipant hashad received prior bevacizumab or iswas not eligible to receive bevacizumab due to medical reasons.
    • EditedParticipant hashad received prior treatment with any PI3Kphosphoinositide 3-kinase, mTORmammalian Target Of Rapamycin or AKTProtein Kinase B inhibitor.
    • EditedParticipant iswas concurrently using other anti-cancer therapy.
    • EditedParticipant iswas in a state of small or large bowel obstruction or hashad other impairment of gastrointestinal (GI) function or GI disease.
    • EditedParticipant has had surgery within 14 days prior to starting study drug or hashad not recovered from major adverse effects.
    • EditedParticipant hashad not recovered from all toxicities related to prior anticancer therapies to baseline or National Cancer Institute (NCI ) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.03 Grade ≤1. Exception to this criterion: participants with any grade of alopecia arewere allowed to enter the study.
    • EditedParticipant hashad an established diagnosis of diabetes mellitus type I or uncontrolled type II based on fasting plasma glucose and HbA1c.
    • EditedParticipant hashad received radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to randomization, and who hashad not recovered to baseline, grade 1 or better from related adverse effects of such therapy (with the exception of alopecia).
    • EditedParticipant has ahad known hypersensitivity to any of the study drugs or excipients.
    • EditedParticipant hashad a history of myelodysplastic syndrome or acute myeloid leukemia, or presentspresented clinical and/ or laboratory features suggestive thereof.
    Secondary outcomes 1 edited, 7 time frame changed, 4 description edited
    What changed in the outcomes
    • EditedArea Under the Curve From Time Zero to the Last Measurable Concentration Sampling Time (AUClast) of Alpelisib and OlaparibTime frame: Day 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
    • Time frameNumber of Participants With Dose Interruptions and Dose ReductionsFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 39 months with alpelisib or olaparib, 45 months with paclitaxel, and 23 months with pegylated liposomal doxorubicin (PLD)
    • Time frameDose Intensity for Alpelisib and OlaparibFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 39 months
    • Time frameDose Intensity for PaclitaxelFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 45 months
    • Time frameDose Intensity for Pegylated Liposomal DoxorubicinFrom randomization until end of treatment, assessed up to approximately 18 months → From randomization until end of treatment, assessed up to approximately 23 months
    • Time frameArea Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and OlaparibDay 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
    • Time frameMaximum Concentration (Cmax) of Alpelisib and OlaparibDay 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
    • Time frameTime to Reach Maximum Concentration (Tmax) of Alpelisib and OlaparibDay 8 Cycle 1 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose), Day 1 on Cycle 2, 4 and 8 (pre-dose) → Cycle 1 Day 8 (pre-dose, 1, 2, 3, 4, 6, 8 and 24 hours post dose)
    • DescriptionArea Under the Curve Calculated to the End of a Dosing Interval (Tau) at Steady-state (AUCtau) of Alpelisib and Olaparib: how it is measured was reworded
    • DescriptionMaximum Concentration (Cmax) of Alpelisib and Olaparib: how it is measured was reworded
    • DescriptionOverall Survival: how it is measured was reworded
    • DescriptionTime to Reach Maximum Concentration (Tmax) of Alpelisib and Olaparib: how it is measured was reworded
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04729387
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Jul 22, 2021
Primary completion
Apr 21, 2023
Completion
Jan 19, 2026
Results posted
Jun 4, 2026
Last update
Oct 19, 2026

Study contacts

Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Alpelisib · Olaparib

Start the discussion